Latest news

Crescent's ADC deal with Kelun & Pharvaris' Phase 3 win in hereditary angioedema

Crescent's ADC deal with Kelun & Pharvaris' Phase 3 win in hereditary angioedema

Joachim Eeckhout
Capricor’s Duchenne comeback & Triana's $120M molecular glue degrader

Capricor’s Duchenne comeback & Triana's $120M molecular glue degrader

Joachim Eeckhout
Janux's T-cell therapy misses the mark

Janux's T-cell therapy misses the mark

Joachim Eeckhout
Belite Bio's Phase 3 success in Stargardt

Belite Bio's Phase 3 success in Stargardt

Joachim Eeckhout
Otsuka’s first FDA-approved anti-APRIL therapy & Valneva's site closure

Otsuka’s first FDA-approved anti-APRIL therapy & Valneva's site closure

Joachim Eeckhout
Daily Snap - 26. November 2025

Daily Snap - 26. November 2025

Joachim Eeckhout
Gilead invests $414M into TREX1 cancer drug from Sprint Bioscience

Gilead invests $414M into TREX1 cancer drug from Sprint Bioscience

Eduardo Longoria
Daily Snap - 25. November 2025

Daily Snap - 25. November 2025

Joachim Eeckhout
Novo Nordisk’s Alzheimer’s trials fail, casting doubt on GLP-1 drugs for neurodegeneration

Novo Nordisk’s Alzheimer’s trials fail, casting doubt on GLP-1 drugs for neurodegeneration

Eduardo Longoria
Versant launches Dayra with $50M Biogen deal to chase oral macrocyclic peptide drugs

Versant launches Dayra with $50M Biogen deal to chase oral macrocyclic peptide drugs

Eduardo Longoria
Daily Snap - 24. November 2025

Daily Snap - 24. November 2025

Joachim Eeckhout
Contineum’s multiple sclerosis drug fails phase 2 test, raising doubts on its potential

Contineum’s multiple sclerosis drug fails phase 2 test, raising doubts on its potential

Eduardo Longoria
FirstBack
56789101112
Next Last